IMUC

ImmunoCellular Therapeutics, Ltd.
IMUC

Overview Fund Activity
Delisted

IMUC was delisted on the 16th of October, 2018.

Back to rankings

36 hedge funds and large institutions have $2.77M invested in ImmunoCellular Therapeutics, Ltd. in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
36
Holders Change
+2
Holders Change %
+5.88%
% of All Funds
0.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
9
Reduced
7
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Goldman Sachs
1
Goldman Sachs
New York
$18K
2
SM
2
Sabby Management
Florida
$1.03M
3
Bank of New York Mellon
3
Bank of New York Mellon
New York
$28K
4
Nomura Holdings
4
Nomura Holdings
Japan
$5K
5
Wells Fargo
5
Wells Fargo
California
$5K

Top Sellers

1
Citadel Advisors
1
Citadel Advisors
Florida
$10K
2
Renaissance Technologies
2
Renaissance Technologies
New York
$334K
3
LPL Financial
3
LPL Financial
California
$0
4
CCC
4
Chelsea Counsel Company
California
$6K
5
Citigroup
5
Citigroup
New York
$5K
Name Holding Trade Value Shares
Change 		Shares
Change %
DOA
26
D'Orazio & Associates
Virginia
$1K – – –
JCM
27
Jacobi Capital Management
Pennsylvania
$1K +$1K +125 New
LPL Financial
28
LPL Financial
California
– -$4K -275 Closed
1
2